Immix Biopharma’s lead asset, IMX-110, is being investigated in a Phase Ib/IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumors in combination with tislelizumab. Its preclinical pipeline is based on tissue-specific therapeutics (TSTx) technology.
CAR-T cell therapies have the potential to provide effective treatments for challenging diseases. However, current available options are not considered outpatient treatments due to the risk of serious side effects. If NXC-201 continues to demonstrate a desirable efficacy and safety profile, it could become the first outpatient CAR-T cell therapy.
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Update
Healthcare |
Flash note
Dr Ilya Rachman
CEO
Gabriel Morris
CFO
Forecast net debt (US$m)
15.1
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (7.3) | 2.4 | 4.9 |
Relative | (6.1) | (4.3) | (11.3) |
52 week high/low | US$7.3/US$1.6 |
Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead study site, the Memorial Sloan Kettering Cancer Center. This US-based study will evaluate the safety and efficacy of NXC-201 in approximately 40 patients with relapsed/refractory amyloid light chain amyloidosis (r/r ALA). Management expects the trial to be fully enrolled within 18 months, implying that top-line results could be available in H126. In the near term, we anticipate rolling data readouts as seen with the prior NEXICART-1 trial. We also expect more details for the expansion of NXC-201 into additional autoimmune indications by the end of 2024.
Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 0.0 | (8.2) | (7.6) | (54.77) | N/A | N/A |
2023A | 0.0 | (16.1) | (13.0) | (75.14) | N/A | N/A |
2024E | 0.0 | (22.0) | (21.4) | (92.69) | N/A | N/A |
2025E | 0.0 | (26.0) | (26.5) | (100.68) | N/A | N/A |